Anti-IGFBP7 treatment significantly alleviated psoriasis-like skin inflammation, with reduced psoriatic scales, skin capillary dilation, erythrocyte exocytosis, epidermal thickening, keratinocyte proliferation, and mRNA levels of psoriatic cytokines and antimicrobial peptides (Figure 9, A–H, and Supplemental Figure 12, B–I). This evidence concerns the gene IGFBP7 and dermatitis.